Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Anti-PD-1 Antibody
- Mmr Deficiency
- MSI-H
- Radiotherapy
- Rectal Cancer
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The patients meet the inclusion criteria. After signing the informed consent, they are given radiotherapy 5Gyx5 and sintilimab 200mg ivgtt D1, D15, D29. Radical surgery is performed 6-8 weeks after radiotherapy.
The patients meet the inclusion criteria. After signing the informed consent, they are given radiotherapy 5Gyx5 and sintilimab 200mg ivgtt D1, D15, D29. Radical surgery is performed 6-8 weeks after radiotherapy.
Tracking Information
- NCT #
- NCT04636008
- Collaborators
- First Affiliated Hospital of Chongqing Medical University
- Yunnan Cancer Hospital
- Sichuan Cancer Hospital and Research Institute
- Chengdu Third People's Hospital
- The Affiliated Hospital Of Southwest Medical University
- Investigators
- Principal Investigator: Meng Qiu, M.D. West China Hospital
Get Well Soon